SLDB · Solid Biosciences Inc.
$9.30
+0.20 (+2.20%)
At close · Aug 21
Market Cap
$997.19M
Shares
107.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.30
Open$9.34
Day$9.23–9.67
52W close$3.93–11.15
Avg vol 30d958K
Short int17.0M · 15.9% float · 16.2d
Short vol50%
Last earningsFeb 18, 2025
DataOct 2022–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Oct 28, 2022; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+4%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+50%
trailing
YTD return
+65%
this year
Relative strength
+38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.89% of float · ▼ -3.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
155 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−41%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-157.4M
Balance sheet
$59.9M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.89% of float · ▼ -3.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
155 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $9 · 74%
Range high $11
vs 200-day avg +32%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLDB
this stock
Solid Biosciences Inc.
|
$997.19M | +64.9% | -40.6% | — | 15.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 28, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLDB | +1.1% | +18.8% | +50.0% | +15.4% | +64.9% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.5% | +15.1% | +38.4% | +12.9% | +52.6% |
Key facts
CIK
1707502
CUSIP
83422E204
13F (30d)
147 filings
143 filers
Visit website
Investor relations